Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes
NVO secures FDA nod for Awiqli, a once-weekly basal insulin for type II diabetes, strengthening its portfolio and showing strong efficacy in studies.
Novo Nordisk: A Comeback Story In The World's Fastest-Growing Drug Market
Novo Nordisk is positioned as a durable No. 2 in the obesity drug market, not a loser to Eli Lilly. NVO is expanding manufacturing, advancing next-generation therapies like CagriSema, and leveraging price leadership and direct-to-consumer channels. With a forward P/E of 11–15x, NVO trades at a deep discount to peers and historical averages, despite strong fundamentals and growth prospects.
Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade
Novo Nordisk (NVO) closed the most recent trading day at $36.33, moving 1.52% from the previous trading session.
NVO Eyes Global Expansion of Diabetes Drug After Strong Phase II Data
Novo Nordisk reports phase II data for UBT251, showing strong HbA1c reduction and weight loss. It plans for global studies and China phase III trials.
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
Novo Nordisk's FDA nod for higher-dose Wegovy could boost healthcare ETFs' appeal, offering diversified exposure to the obesity drug market.
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
Novo Nordisk faces slowing growth and rising competition, while Structure Therapeutics shows strong obesity study results, highlighting a clash of stability vs. upside.
India is launching cheap, weight-loss drugs and Novo Nordisk is betting on its brands to stay on top
Novo lost semaglutide patent protection in India, triggering generic launches. Indian drugmakers launched generic versions at lower prices.
Novo Nordisk's Higher Dose Wegovy Weight-Loss Drug Gains U.S. Approval
The Danish drugmaker said the accelerated approval was based on results from its Step Up trial, which showed 20.7% mean weight loss for participants with obesity.
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
The Food and Drug Administration approved a higher dose version of Novo Nordisk's blockbuster weight loss injection Wegovy, as the company pushes to win back market share from Eli Lilly. The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.
Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India
India's market for diabetes and weight-loss drugs is set for a shake-up as Danish drugmaker Novo Nordisk's patent on semaglutide expires this week, triggering a wave of cheaper generics from local drugmakers and worries about uneven oversight in an overcrowded market.
Novo Nordisk (NVO) Declines More Than Market: Some Information for Investors
Novo Nordisk (NVO) closed the most recent trading day at $37.45, moving 2.55% from the previous trading session.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
